Application procedure
Astellas Withdraws European Application for Geographic Atrophy Treatment Izervay
Astellas, Izervay, geographic atrophy, European application withdrawal, avacincaptad pegol
Capricor Secures $35M Deal for European Rights to DMD Therapy Ahead of FDA Application
Capricor Therapeutics, Duchenne muscular dystrophy (DMD), cell therapy, FDA application, European rights, $35M deal
Gilead Sciences Receives $210 Million Venture Capital Funding to Expand Trodelvy’s Application in Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Carcinoma, Capital, Trodelvy, Trodelvy’s, Application procedure